Sugi Predict

Sugi Predict / Compounds / SCHEMBL2087613

SCHEMBL2087613

SCHEMBL2087613

O=C(O)c1cn(-c2ccc(F)cc2F)c2cc(Cl)c(F)cc2c1=O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ KDM4E B2RXH2 3/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ HPGD P15428 2/20 0.52
▸ HSD17B10 Q99714 2/20 0.52
▸ EPHA2 P29317 1/20 0.51
▸ FLT4 P35916 1/20 0.51
▸ GSK3B P49841 1/20 0.51
▸ RARB P10826 1/20 0.51
▸ TBXAS1 P24557 1/20 0.51
▸ SLC6A3 Q01959 1/20 0.51
▸ POLB P06746 2/20 0.46
▸ XBP1 P17861 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ NFKB2 Q00653 1/20 0.46
▸ RELA Q04206 1/20 0.46
▸ RORC P51449 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6216178 0.95 LMNA (0.50) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL28331830 0.91 LMNA (0.43) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL500692 0.90 LMNA (0.56) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL9046825 0.87 LMNA (0.51) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL9443624 0.87 LMNA (0.46) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL9147090 0.86 EPHA2 (0.53) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL8094560 0.86 EPHA2 (0.53) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL8137856 0.86 LMNA (0.39) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL10330764 0.86 LMNA (0.55) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL9045221 0.86 ALDH1A1 (0.46) LMNAKMT2AMEN1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1990000551-A1 PROCESS FOR THE PREPARATION OF QUINOLINE ANTIBACTERIAL COMPOUNDS ABBOTT LABORATORIES (US) 1990-01-25 — — WO claimed
EP-0350950-A1 Process for the preparation of quinoline antibacterial compounds ABBOTT LABORATORIES (US) 1990-01-17 — — EP claimed
CN-110551124-B Quinolone compound or agriculturally and pharmaceutically acceptable salt thereof, and preparation method and application thereof 山东省联合农药工业有限公司 2021-01-08 — — CN disclosed
CN-108285469-B Antibacterial quinolone derivative and preparation method and application thereof 遵义医学院 2020-07-24 — — CN disclosed
CN-110551124-A quinolone compound or agriculturally and pharmaceutically acceptable salt thereof, and preparation method and application thereof SHANDONG UNITED PESTICIDE IND CO LTD 2019-12-10 — — CN disclosed
US-8329908-B2 Dual action antibiotics MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) 2012-12-11 — — US disclosed
US-20110059946-A1 DUAL ACTION ANTIBIOTICS MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMBINATORISCHE CHEMIE (DE) 2011-03-10 — — US disclosed
US-7820823-B2 Dual action antibiotics Morphochem Aktiengesellschaft Fur Kominatorische Chemi (DE) 2010-10-26 — — US disclosed
US-20050096343-A1 Dual action antibiotics MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) 2005-05-05 — — US disclosed
WO-2003031443-A1 DUAL ACTIONS ANTIBIOTICS COMPRISING A OXAZOLDINONE AND A QUINOLONE OR NAPHTHYRIDINONE MOIETY Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2003-04-17 — — WO disclosed
EP-0704443-B1 Quinolone and naphthyridone carboxylic acid derivatives BAYER AG (DE) 2000-12-27 — — EP disclosed
EP-0520277-A2 7-Azaisoindolinyl-quinolone- and naphthyridoncarboxylic acid derivatives BAYER AG (DE) 1992-12-30 — — EP disclosed
EP-0520240-A1 7-Isoindolinyl-quinolone and naphthyridonecarboxylic acid derivatives BAYER AG (DE) 1992-12-30 — — EP disclosed
US-5045549-A Bactericides CHEMIE LINZ GESELLSCHAFT M.B.H. (AT) 1991-09-03 — — US disclosed
EP-0422485-A2 Quinolone carboxylic acid derivatives, process for their preparation and their use BAYER AG (DE) 1991-04-17 — — EP disclosed
EP-0251308-B1 4-QUINOLONE-3-CARBOXYLIC-ACID DERIVATIVES, PROCESS FOR THEIR SYNTHESIS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM Chemie Linz Gesellschaft m.b.H. (AT) 1990-11-22 — — EP disclosed
WO-1990000551-A1 PROCESS FOR THE PREPARATION OF QUINOLINE ANTIBACTERIAL COMPOUNDS ABBOTT LABORATORIES (US) 1990-01-25 — — WO disclosed
EP-0350950-A1 Process for the preparation of quinoline antibacterial compounds ABBOTT LABORATORIES (US) 1990-01-17 — — EP disclosed
US-4730000-A 7-SUBSTITUTED AMINO-6-FLUORO-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXYLIC ACIDS AND ESTERS ABBOTT LABORATORIES (US) 1988-03-08 — — US disclosed
EP-0251308-A1 4-Quinolone-3-carboxylic-acid derivatives, process for their synthesis and pharmaceutical preparations containing them Chemie Linz Gesellschaft m.b.H. (AT) 1988-01-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096343-A1 Dual action antibiotics SLC11A2, MRPL21, MAP2K5 LMNA 3271/4885KMT2A 4293/4885MEN1 2774/4885
US-20110059946-A1 DUAL ACTION ANTIBIOTICS SLC11A2, MRPL21, MAP2K5 LMNA 3185/4885KMT2A 4381/4885MEN1 3326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.